Respiratory Syncytial Virus Mrna Vaccine 0.5 mL Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 0.5 mL
Reference Brands: mRESVIA (USA/EU)
Category: Vaccines
mRESVIA is an mRNA vaccine designed to protect adults against lower respiratory tract disease (LRTD) caused by RSV. It works by instructing the body to produce a harmless RSV F protein fragment, triggering immune protection. Administered as a single 0.5 mL intramuscular injection, it is indicated for adults 60 years and older and adults 18–59 at increased risk. It is the first non‑COVID‑19 mRNA vaccine approved in several regions. Common side effects include pain at injection site, fatigue, headache, and muscle aches.
Product Description:
mRESVIA is a messenger RNA (mRNA) vaccine developed to actively immunize adults against lower respiratory tract disease (LRTD) caused by Respiratory Syncytial Virus (RSV), which can cause severe lung infections, particularly in older adults and at-risk populations. The vaccine contains nucleoside-modified mRNA (mRNA‑1345) encoding a stabilized RSV F glycoprotein in its prefusion form. When administered as a 0.5 mL intramuscular injection, the mRNA instructs the recipient’s cells to produce the RSV F protein fragment, stimulating the immune system to generate protective antibodies without using live virus. mRESVIA is indicated for adults 60 years and older and adults 18 through 59 who are at increased risk of severe RSV disease. The vaccine may cause mild to moderate side effects such as pain at the injection site, fatigue, headache, muscle pain, joint pain, and chills. Its approval marks one of the first uses of mRNA technology for a disease other than COVID‑19, demonstrating the potential of mRNA vaccines to prevent other viral illnesses in adults.
Respiratory Syncytial Virus Mrna Vaccine — third party manufacturing & bulk supply
Respiratory Syncytial Virus Mrna Vaccine 0.5 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Respiratory Syncytial Virus Mrna Vaccine listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Respiratory Syncytial Virus Mrna Vaccine →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
mRESVIA is used to actively immunize adults against
mRESVIA is an mRNA vaccine formulated with
The trade name of this RSV mRNA vaccine is
mRESVIA is manufactured by
The generic name of mRESVIA is
The brand name of the RSV mRNA vaccine is
mRESVIA is manufactured under regulated pharmaceutical conditions by
Related Products
Inactivated Vaccines
Strength:
Dose and concentration depend on formulations
Form: Injectable suspension (IM administration), Lyophilized powder for reconstitution
Reference Brands: Sinovac Coronavac. Covaxin(EU)
View Details
Viral Vector Vaccines
Strength:
0.5 mL
Form: Intramuscular injectable suspension (IM)
Reference Brands: US: Johnson & Johnson’s Janssen (Jcovden)
View Details
Mrna-Based Vaccines
Strength:
30 µg and 100 µg
Form: Injectable suspension
Reference Brands: Comirnaty, Spikevax(US)
View Details
Meningococcal Vaccine
Strength:
0.5 mL
Form: Vial or pre-filled syringe (injectable), Conjugate vaccines
Reference Brands: Menactra, Menveo(US), NmVac4-DT (India)
View DetailsQuick Response Guaranteed | Verified Suppliers
